![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KNG1 |
Gene summary for KNG1 |
![]() |
Gene information | Species | Human | Gene symbol | KNG1 | Gene ID | 3827 |
Gene name | kininogen 1 | |
Gene Alias | BDK | |
Cytomap | 3q27.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | P01042 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3827 | KNG1 | NAFLD1 | Human | Liver | NAFLD | 1.73e-11 | 8.50e-01 | -0.04 |
3827 | KNG1 | S42 | Human | Liver | HCC | 1.91e-03 | 7.98e-01 | -0.0103 |
3827 | KNG1 | S43 | Human | Liver | Cirrhotic | 3.07e-04 | -3.11e-02 | -0.0187 |
3827 | KNG1 | HCC1_Meng | Human | Liver | HCC | 3.95e-78 | 4.13e-01 | 0.0246 |
3827 | KNG1 | HCC2_Meng | Human | Liver | HCC | 1.38e-16 | -4.86e-01 | 0.0107 |
3827 | KNG1 | HCC1 | Human | Liver | HCC | 9.38e-42 | 6.55e+00 | 0.5336 |
3827 | KNG1 | HCC2 | Human | Liver | HCC | 1.35e-51 | 6.53e+00 | 0.5341 |
3827 | KNG1 | HCC5 | Human | Liver | HCC | 1.30e-07 | 3.91e+00 | 0.4932 |
3827 | KNG1 | Pt13.a | Human | Liver | HCC | 5.24e-10 | 2.42e-01 | 0.021 |
3827 | KNG1 | Pt13.b | Human | Liver | HCC | 6.34e-33 | 1.72e-01 | 0.0251 |
3827 | KNG1 | Pt14.a | Human | Liver | HCC | 1.06e-05 | 1.84e-01 | 0.0169 |
3827 | KNG1 | Pt14.b | Human | Liver | HCC | 6.02e-26 | 7.69e-01 | 0.018 |
3827 | KNG1 | Pt14.c | Human | Liver | HCC | 8.86e-06 | 7.74e-01 | 0.0054 |
3827 | KNG1 | Pt14.d | Human | Liver | HCC | 1.34e-16 | 6.34e-01 | 0.0143 |
3827 | KNG1 | S015 | Human | Liver | HCC | 3.00e-02 | -4.81e-01 | 0.2375 |
3827 | KNG1 | S016 | Human | Liver | HCC | 6.10e-09 | -4.92e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:1903035 | Liver | NAFLD | negative regulation of response to wounding | 26/1882 | 94/18723 | 1.18e-06 | 5.66e-05 | 26 |
GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
GO:00030182 | Liver | NAFLD | vascular process in circulatory system | 46/1882 | 263/18723 | 1.36e-04 | 2.58e-03 | 46 |
GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa05142 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa051421 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KNG1 | SNV | Missense_Mutation | novel | c.421N>A | p.Asp141Asn | p.D141N | P01042 | protein_coding | tolerated(0.55) | benign(0) | TCGA-O2-A52V-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
KNG1 | SNV | Missense_Mutation | novel | c.1730N>T | p.Ser577Leu | p.S577L | P01042 | protein_coding | tolerated(0.29) | benign(0) | TCGA-BA-A6DE-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KNG1 | SNV | Missense_Mutation | novel | c.93N>T | p.Lys31Asn | p.K31N | P01042 | protein_coding | tolerated(0.11) | benign(0.029) | TCGA-CV-6943-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
KNG1 | SNV | Missense_Mutation | novel | c.1811N>T | p.Ser604Leu | p.S604L | P01042 | protein_coding | deleterious(0) | benign(0.154) | TCGA-HD-7229-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
KNG1 | SNV | Missense_Mutation | rs779764784 | c.394G>A | p.Glu132Lys | p.E132K | P01042 | protein_coding | tolerated(0.24) | benign(0.017) | TCGA-KU-A6H7-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
KNG1 | SNV | Missense_Mutation | c.976N>G | p.Thr326Ala | p.T326A | P01042 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-4368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
KNG1 | SNV | Missense_Mutation | c.1346N>A | p.Arg449His | p.R449H | P01042 | protein_coding | tolerated(1) | benign(0) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
KNG1 | SNV | Missense_Mutation | c.630N>G | p.Asn210Lys | p.N210K | P01042 | protein_coding | tolerated(0.34) | benign(0.017) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
KNG1 | SNV | Missense_Mutation | c.1469N>C | p.Val490Ala | p.V490A | P01042 | protein_coding | deleterious(0.01) | benign(0) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
KNG1 | SNV | Missense_Mutation | rs369801278 | c.719N>A | p.Arg240Gln | p.R240Q | P01042 | protein_coding | tolerated(0.18) | benign(0.005) | TCGA-CG-4465-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3827 | KNG1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | hormonal contraceptives for systemic use | 28750087 | ||
3827 | KNG1 | DRUGGABLE GENOME, PROTEASE INHIBITOR | Avoralstat | AVORALSTAT |
Page: 1 |